Cancer Res Treat. 2011;43(3):154-159 Table 1. Patient characteristics Total Median age (range, yr) Gender Male Female ECOG performance status 0-1 2 Disease status Metastatic Recurrent Site of metastasis Lymph node Liver Abdominal pelvic mass Lung Others No. of organs involved 1 2 3 Complete response Partial response Stable disease Progressive disease Not assessable Overall response rate (%) Disease control rate (%) ECOG, Eastern Cooperative Oncology Group. Table 2. Response rates of patients No. of patients (%) 39 62 (38-78) 22 (56.4) 17 (43.6) 37 (94.9) 2 (5.1) 31 (79.5) 8 (20.5) 19 (48.7) 12 (30.8) 9 (23.1) 6 (15.4) 7 (18.0) 17 (43.6) 11 (28.2) 11 (28.2) No. of patients (%) (n=39) 0 (0) 11 (28.2) 14 (35.9) 7 (17.9) 7 (17.9) 28.2 64.1 the 95% confidence interval (CI) for the median time-to-event was computed. The Cox proportional hazard method was used for assessing independent prognostic factors. Statistical significance was calculated at the 95% CI (p 0.05). All the analyses were performed using SPSS ver. 14.0 (SPSS Inc., Chicago, IL). R e s u l t s 1 156 Patient characteristics CANCER RESEARCH AND TREATMENT Between January 2006 and August 2009, 39 patients with a median 1.0 l a v i v ur 0.8 s f o y ilit 0.6 b a b o pr 0.4 e v i t a ul 0.2 m u C 0.0 1.0 l a v i v ur 0.8 s f o y ilit 0.6 b a b o pr 0.4 e v i t a ul 0.2 m u C 0.0 18 3.0 Median: 4.3 mo (95% confidence interval, 2.0 to 6.5 mo) 0 6 (mo) 12 Fig. 1. Kaplan-Meier curve for time-to-progression. Median: 9.8 mo (95% confidence interval, 3.5 to 16.0 mo) 0.0 1.0 (yr) 2.0 Fig. 2. Kaplan-Meier curve for overall survival. age of 62 years (range, 38 to 78 years) were retrospectively studied in Seoul, Bucheon, and Cheonan Soonchunhyang University Hospitals. There were 22 men and 17 women, and 2 patients (5.1%) had an ECOG performance status of 2. Thirty-one patients (79.5%) had pri- mary metastatic disease and 8 patients (20.5%) had recurrent disease. Lymph nodes were the most common metastatic sites. The metastasis involved two organs in 11 patients (28.2%) and 3 organs in 11 patients (28.2%). Eight patients who had previously undergone cu- rative surgery received adjuvant 5-FU-containing chemotherapy. The majority of the patients (71.8%) had 1 or 2 involved regions, and the common target lesion was a lymph node or the liver. The patient baseline characteristics are listed in Table 1. 2 Tumor responses and survival Thirty-two of the 39 patients were evaluable for response according to the RECIST criteria (ver. 1.0). The response was not assessable in 7 patients who were lost to follow-up (n=3), voluntary refusal for further treatment after 1 or 2 cycles (n=2), and death before the 4 cycles of